Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 4,117 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Healthy Subjects
Interventions: Percutaneous Electrical Nerve Field Stimulation (PENFS); Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Heroin Dependence
Interventions: Intranasal challenge drug; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 45 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid-use Disorder, Amphetamine Use Disorders
Interventions: Neurocognitive Empowerment for Addiction Treatment (NEAT), Active Control; Behavioral
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Fever, Temperature Monitoring
Interventions: Moni-Patch Temperature Monitoring Patch System, Continuous Tympanic Temperature Monitoring System; Device
Lead sponsor: Murata Vios, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Influenza
Interventions: Investigational H9N2 vaccine GSK2654911A, Investigational H9N2 vaccine GSK2654909A, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 422 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Miami, Florida • Edison, New Jersey • Austin, Texas

Conditions: Dyspepsia, Gastroparesis, Anxiety, Depression
Interventions: Poetry, Poetry Manual; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cancer, Solid Tumor
Interventions: Fludarabine, Cyclophosphamide, IMA101 product, Recombinant human interleukin-2, IMADetect, Atezolizumab; Drug · Biological · Diagnostic Test
Lead sponsor: Immatics US, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Dentin Sensitivity
Interventions: Dissolvable polymer strip containing Novamin (calcium sodium phosphosilicate); Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Burns, Wound Infection
Interventions: Methylene Blue, Blue Light Illumination; Drug · Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: No Specific Medical Conditions or Disease States
Interventions: Telemetry and manual monitoring vs Contactless monitoring devices; Device
Lead sponsor: Turtle Shell Technologies Pvt. Ltd.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Immunization Rate
Interventions: Text Message Reminder/Recall, Parent Preference; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 11 Years to 17 Years
Enrollment: 34,581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Emphysema, COPD
Interventions: IBV® Valve System; Device
Lead sponsor: Olympus Corporation of the Americas; Industry
Eligibility: 40 Years to 74 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 34
States / cities: Birmingham, Alabama • Los Angeles, California • Mission Viejo, California + 29 more

Conditions: Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Squamous Cell Carcinoma of Skin, Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions: Blood Specimen Collection, Tumor Tissue Collection, Medical Record Review; Procedure · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Major Depression, Major Depression Disorders
Interventions: Transcranial Direct Current Stimulation (tDCS); Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Urinary Retention, Surgery
Interventions: Voiding Trial; Procedure
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Pain Management, Opioid Consumption
Interventions: Placebo, Oxycodone 5 mg, Multimodal Non-Opioid Analgesia; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Bronchoscopic Biopsy, Blood Sample; Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Buffalo, New York

Conditions: Mechanical Ventilation, Pediatric Acute Respiratory Failure, Analgesics, Opioid, Sedation and Analgesia
Interventions: Acetaminophen, Ketorolac, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 2 Months to 17 Years
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 16
States / cities: Little Rock, Arkansas • Washington D.C., District of Columbia • Ann Arbor, Michigan + 13 more

Conditions: Motor Activity
Interventions: Motor Learning, Somatosensory Learning, Observational Task, Mental Imagery, transcranial direct current stimulation; Behavioral · Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma
Interventions: Brentuximab Vedotin, Bendamustine, Neulasta; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Visual Performance
Interventions: TRP-200, ACUVUE Oasys 1-Day; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Diabetes Mellitus, Type 2
Interventions: NNC0662-0419, Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 23
States / cities: Lancaster, California • Lomita, California • Long Beach, California + 20 more

Conditions: Candida Vulvovaginitis
Interventions: Fluconazole, SCY-078; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 22 more

Conditions: Visual Acuity
Interventions: JJVC Investigational Multifocal Contact Lens (senofilcon A c3), Dailies Total 1® Multifocal Contact Lens; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 7
States / cities: Jacksonville, Florida • Maitland, Florida • Pittsburg, Florida + 3 more

Search by objective public record fields.

ABVN Phase 2 - PENFS

Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone

Neurocognitive Empowerment for Addiction Treatment (NEAT) in Opioid Use Disorder and Amphetamine Use Disorder

Accuracy of Moni-Patch Compared With Tympanic Temperature Monitoring in Adults at Risk of Fever

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age

Virtual Poetry Workshops to Enhance Patient Well Being and Reduce Anxiety

ACTolog in Patients With Solid Cancers

To Evaluate the Efficacy of an Experimental Dissolvable Strip in Rapidly Relieving Dentinal Hypersensitivity (DH)

Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection

Pilot Clinical Evaluation of Dozee VS, a Contactless Continuous Vital Parameters Monitoring System in Hospital Patients

Adolescent Vaccination in the Medical Home: Established and Innovative Strategies

Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema

Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma

Accelerated High-Dose tDCS for Depression

Efficacy of Retrograde Fill Vs Spontaneous Fill to Assess Voiding Function

Opioid-Sparing Joint Replacement

A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer

Optimizing Pain Treatment in Children On Mechanical Ventilation

Investigating Motor Cortex Processing for Pain Modulation

Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)

Visual Performance of Senofilcon A With and Without a New UV/HEV-filter

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

Evaluation of a Daily Disposable Novel Multifocal Contact Lens in a Myopic Population